Figure 2
From: Real-world experience of angiotensin receptor neprilysin inhibitor on the glucose-lowering effect
Changes in the mean HbA1c levels and standard error of the means by treatment group at the baseline, 6-month, 12-month, 18-month, and 24-month visits.
